• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Neurelis Inc.

FDA accepts NDA for intranasal epinephrine from ARS Pharmaceuticals

December 8, 2022 By Sean Whooley

ARS pharmaceuticals neffy neurelis

ARS Pharmaceuticals announced today that the FDA accepted its new drug application (NDA) for neffy, its intranasal epinephrine. The offering covers the emergency treatment of severe type I allergic reactions in children and adults weighing 30 kg (66 pounds) or more. The company set an anticipated target action date of mid-2023 for its PDUFA (Prescription […]

Filed Under: Business/Financial News, Drug-Device Combinations, Food & Drug Administration (FDA), Pharmaceuticals Tagged With: arspharmaceuticals, Neurelis Inc.

Neurelis closes $114M Series D for diazepam nasal spray

March 10, 2021 By Sean Whooley

Neurelis

Neurelis announced today that it closed a $114 million Series D financing round to support its lead orphan drug product. San Diego-based Neurelis’ Valtoco (diazepam nasal spray) is a proprietary formulation incorporating the science of Intravail transmucosal absorption enhancement technology. The drug enables the noninvasive delivery of a range of drugs, while the company focuses […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Neurological Tagged With: Neurelis Inc.

Neurelis wins FDA approval for seizure rescue nasal spray

January 13, 2020 By Danielle Kirsh

neurelis-logo

Neurelis today said it won FDA approval for its Valoco seizure rescue nasal spray. Valtoco is approved to use by a care partner outside of a medical setting to treat intermittent, stereotypic episodes of seizure activity. It is designed for people with epilepsy aged 6 or older. Valtoco also uses the company’s Intravail formula for […]

Filed Under: Drug-Device Combinations Tagged With: Neurelis Inc.

Neurelis closes Series B for intranasal diazepam spray

January 5, 2017 By Sarah Faulkner

Neurelis closes Series B for intranasal diazepam spray

Neurelis, Inc. said today that it closed a Series B financing round, led by HBM Healthcare Investments. Other investors included LYZZ Capital, which previously led a Series A funding round for the company. Neurelis will use the funds to complete clinical trials for its intranasal diazepam spray and prepare a new drug application to submit […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Funding Roundup, Neurological Tagged With: Neurelis Inc.

Neurelis wins fast track designation from FDA for intranasal diazepam spray

January 4, 2017 By Sarah Faulkner

Neurelis closes Series B for intranasal diazepam spray

Neurelis, Inc. said today that it won fast track designation from the FDA for its intranasal diazepam spray. The  nasal formulation of diazepam, which is being developed for pediatric and adult epilepsy patients who experience repititive or cluster seizures, is in the final stage of clinical development, according to Neurelis. The company expects to submit […]

Filed Under: Featured, Food & Drug Administration (FDA), Neurological, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Neurelis Inc.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS